Anchor Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Anchor Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27K	Hold	347	–	–	﹤0.01%	1135
2026 Q1	$1.06K	Hold	347	–	–	﹤0.01%	1021
2025 Q4	$1.42K	Hold	347	–	–	﹤0.01%	993
2025 Q3	$1.69K	Hold	347	–	–	﹤0.01%	995
2025 Q2	$1.76K	Hold	347	–	–	﹤0.01%	969
2025 Q1	$1.84K	Hold	347	–	–	﹤0.01%	956
2024 Q4	$2.35K	Buy	+347	New	+$2.33K	﹤0.01%	930

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Anchor Investment Management's RXRX Position: Q2 2026 in Review

Anchor Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 347 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Anchor Investment Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.35K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Anchor Investment Management held 347 shares of Recursion Pharmaceuticals worth $1.27K as of Q2 2026.
Anchor Investment Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Anchor Investment Management's portfolio in Q2 2026, its #1135 holding.
Anchor Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Anchor Investment Management's Recursion Pharmaceuticals position peaked at $2.35K in Q4 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Anchor Investment Management's 13F filing for Q2 2026, filed 15 Sep 2026.